TissueTech Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug TTBT01
Share this article Share this article MIAMI, March 1, 2021 /PRNewswire/ -- Bio-Tissue, Inc., a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today that its parent company TissueTech had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using morselized Cryopreserved Amniotic Membrane (CAM) and Cryopreserved Umbilical Cord (CUC) Investigational New Drug (IND) TTBT01. This clearance represents another milestone as the company works to achieve FDA approval for its graft and morse...
Source: prnewswire.com